PMC8126709_01
PMC8126709_02
Chest CT scans on day 3 after admission (A) without signs of COVID-19 and day 34 (B) showing COVID-19 pneumonia.
fimmu-12-645989-g001.jpg
PMC8126709_04_fimmu-12-645989-g001.jpg
f1
On d33 of follow-up the patient presented without overt symptoms, but oxygen saturation was 93% and a CT-scan showed signs of COVID-19 pneumonia (Figure 1). Infusion of three additional units of CP from a different donor (donor-2; d60, d62, d64; IgA/IgG OD-ratio: 8.58/6.44; NT-titer: 1:80) resulted in undetectable viral concentration on NP swabs and increased anti-SARS-CoV-2 antibodies in the patient's serum above the detection limit (IgA/IgG OD-ratio: 2.78/2.96) (Figure 1).
PMC8126709_03
PMC8126709_04
Chest CT scans on day 3 after admission (A) without signs of COVID-19 and day 34 (B) showing COVID-19 pneumonia.
fimmu-12-645989-g001.jpg
PMC8126709_04_fimmu-12-645989-g001.jpg
f1
On d33 of follow-up the patient presented without overt symptoms, but oxygen saturation was 93% and a CT-scan showed signs of COVID-19 pneumonia (Figure 1). Infusion of three additional units of CP from a different donor (donor-2; d60, d62, d64; IgA/IgG OD-ratio: 8.58/6.44; NT-titer: 1:80) resulted in undetectable viral concentration on NP swabs and increased anti-SARS-CoV-2 antibodies in the patient's serum above the detection limit (IgA/IgG OD-ratio: 2.78/2.96) (Figure 1).
SARS-CoV-2 viral concentration (VC) in nasopharyngeal swabs (in red) and spike specific SARS-CoV-2 antibody titers over time (in blue). Cell culture was used to determine viral replication as well as presence of neutralizing antibodies (Ab). Application of remdesivir (RDV) over 10 days is depicted in grey. Application of convalescent plasma from 2 different donors is depicted as dotted green lines (light green = 3 units from donor-1; dark green = 3 units from donor-2).
fimmu-12-645989-g002.jpg
PMC8126709_04_fimmu-12-645989-g002.jpg
f2
Remdesivir treatment reduced viral concentrations from 1.95 x 107 copies/ml to 5.35 x 104 copies/ml (Figure 2).